Cellectis S.A.
NASDAQ:CLLSBiotechnology
-$0.02 today
- Market cap
- $103.75M
- Beta
- 2.75
- P/E (TTM)
- -4.6
- EPS (TTM)
- -$0.67
Volume 0.01M
Average 0.04M
CLLS Free Cash Flow
Operating cash flow minus capital expenditures: cash available for debt repayment, dividends, and buybacks.
Cellectis S.A.NASDAQ: CLLS
Free Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Free cash flow declines year over year
Q1 FY2026 free cash flow of $15.82M (cash outflow) fell 9.9% year over year, ahead of the -259.5% change in trailing-twelve-month free cash flow. Sequentially, it rose 44.5% from the prior quarter. Over 3 fiscal years it compounded at -22.1% a year.
Context
- Free cash flow amounted to 58.3% of revenue in FY2025, up 11.2 pp from a year earlier.
- Free cash flow increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth of -9.9% holds above the trailing-twelve-month pace of -259.5%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Free Cash Flow history
USD · from the cash flow
- Latest · FY2025
- (42.5M) USD
- Year-over-year change
- -317.7%
| Period | Period end | Free Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (42.5M) | -317.7% |
| FY2024 | 2024-12-31 | 19.52M | +175.6% |
| FY2023 | 2023-12-31 | (25.82M) | +71.3% |
| FY2022 | 2022-12-31 | (89.89M) | +27.0% |
| FY2021 | 2021-12-31 | (123.12M) | — |
Free Cash Flow vs competitors
How CLLS compares with its peers on the latest reported figures
- Peers report in different currencies, so free cash flow is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -259.5% is the lowest of 9, against a peer median of +4.3%.
- Free cash flow amounts to 59.0% of revenue for CLLS, versus a peer median of 1962.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $151.54M USD | +67.5% | +29.0% | — | |
| LTM Mar 2026 | $131.32M USD | +50.2% | +60.0% | — | |
| LTM Mar 2026 | $70.6M USD | -5.9% | +10.3% | 1837.7% | |
| LTM Dec 2025 | CHF 70.1M CHF | -207.4% | -3.6% | 1962.0% | |
| LTM Mar 2026 | $65.67M USD | — | +2.7% | 7126.6% | |
| LTM Mar 2026 | $62.86M USD | +14.6% | +34.8% | — | |
| LTM Mar 2026 | $40.14M USD | -259.5% | -22.1% | 59.0% | |
| LTM Dec 2025 | $32.76M USD | — | +9.7% | — | |
| LTM Mar 2026 | $26.96M USD | -19.5% | -14.1% | 5391.1% | |
| LTM Mar 2026 | $25.99M USD | -43.1% | -16.2% | — | |
| LTM Mar 2026 | $25.51M USD | +182.6% | — | 11.9% | |
| Peer median (excluding CLLS) | — | +4.3% | +9.7% | 1962.0% | |
Competitors are the stored peer set for CLLS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (96.75M) | (98.69M) | (116.84M) | (36.7M) | (67.8M) |
| Depreciation & Amortization | 14.16M | 18.44M | 18.52M | 19.84M | 20.12M |
| Deferred Income Tax | 0 | 87K | 371K | 0 | 0 |
| Stock-Based Compensation | 11.49M | 6.04M | 5.23M | 0 | 0 |
| Change in Working Capital | (12.3M) | (5.72M) | (3.99M) | 53.57M | (41.72M) |
| Accounts Receivables | (12.44M) | (8.99M) | 2.25M | (6.72M) | (4.44M) |
| Inventory | 215K | 0 | 0 | 0 | 0 |
| Accounts Payables | 177K | 3.25M | (6.31M) | 2.05M | (3.27M) |
| Other Working Capital | (252K) | 23K | 67K | 58.24M | (34.01M) |
| Other Non-Cash Items | (21.17M) | (7.6M) | 71.95M | (14.61M) | 49.26M |
| Operating Cash Flow | (104.56M) | (87.44M) | (24.75M) | 22.1M | (40.14M) |
| Capital Expenditures | (18.56M) | (2.44M) | (1.07M) | (2.58M) | (2.37M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (143K) | 0 | 0 | (162.48M) | (160.27M) |
| Sales of Investments | 15M | 126K | 0 | 63.69M | 134.24M |
| Other Investing Activities | 10.97M | (456K) | (14.44M) | 0 | 0 |
| Investing Cash Flow | 7.28M | (2.76M) | (15.51M) | (102.63M) | (29.58M) |
| Debt Repayment | (10.64M) | (6.6M) | 24.56M | 18.17M | (5.4M) |
| Common Stock Issued | 44.64M | 0 | 67.94M | 82.68M | 44.14K |
| Common Stock Repurchased | 0 | (569K) | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 13.53M | 8.32M | (9.64M) | (11.04M) | (10.85M) |
| Financing Cash Flow | 47.53M | 1.15M | 82.87M | 89.8M | (16.2M) |
| Effect of Forex Changes | (5.75M) | (3.36M) | 884K | (2.73M) | 6.24M |
| Net Change in Cash | (55.51M) | (92.42M) | 43.49M | 6.54M | (79.67M) |
| Free Cash Flow | (123.12M) | (89.89M) | (25.82M) | 19.52M | (42.5M) |
Cellectis S.A.
NASDAQ:CLLS
Intrinsic Alpha fair value
Locked
Current Price
$1.03
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.